Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL) – PRNewswire
CONTEXT: Report of new data to be presented by Abbvie at the European Hematology Association (EHA) Virtual Congress derived from the informCLLTM registry assessing how real-word treatment patterns align with Continue Reading
